Sarepta Therapeutics, Inc. - 8-K Filing
Sarepta Therapeutics appoints Michael Severino as CEO effective July 28, 2026 and enters into a $35M equity compensation package. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 7.01 Regulation FD Disclosure The Company issued a press release in connection with the announcement of Dr, 9.01 Financial Statements and Exhibits Exhibit Number Description 10)
Tickers: $SRPT